Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS010 in Cancer Cachexia
NCT07530666Phase 2Not yet recruiting
- Sponsor
- Dartsbio Pharmaceutical
- Start
- Apr 2026
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of DS010 in cancer cachexia, sponsored by Dartsbio Pharmaceutical. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
DS010
03
Conditions
cancer cachexia
Beyond the preview
Go deeper on NCT07530666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07530666.